Italfarmaco announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil and distribute givinostat (Duvyzat), Italfarmaco’s novel histone deacetylase (HDAC) inhibitor to treat Duchenne muscular dystrophy (DMD). According to the terms of the agreement, Multicare will manage supply and distribution operations for the drug within Brazil. No financial terms were disclosed. – Read: What is Duvyzat? –
“At Italfarmaco, our commitment to rare diseases drives every decision we make. Access to givinostat can have a meaningful impact for patients in Brazil living with DMD,” said Antonio Nardi, Vice President and Head of Business & Portfolio Development of Italfarmaco. “Partnering with Multicare, a leader in the field of rare and highly complex diseases with extensive reach across Brazil, allows us to bring this innovative treatment to those who need it most.”
